ArticleFrontiers in endocrinology2026
Case Report: Morphologically striking eruptive xanthomas with lobulated papules: a sentinel sign of severe metabolic dysregulation.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eruptive xanthoma (EX) is a rare but clinically important dermatologic manifestation of severe hypertriglyceridemia and often serves as a cutaneous indicator of profound disturbances in glucose metabolism. Here, we describe a 27-year-old man who presented with numerous yellowish papules that clustered into lobulated, cauliflower-like plaques on the trunk and limbs, serving as the first clinical indication of underlying metabolic dysregulation. Laboratory investigations revealed extreme hypertriglyceridemia (60.45 mmol/L) and newly diagnosed diabetes mellitus (HbA1c 14.1%). Skin biopsy demonstrated foamy histiocytes and Touton giant cells in the dermis. The patient received combination therapy with fenofibrate (200 mg/day), intensive insulin therapy, and a low-fat diabetic diet, leading to rapid normalization of triglyceride levels from 60.45 mmol/L to 2.47 mmol/L by Day 32. The cutaneous lesions flattened and progressively regressed in parallel with metabolic improvement, leaving only faint post-inflammatory hyperpigmentation at the final evaluation. This case emphasizes that uncommon lobulated morphology may serve as an early visual clue of eruptive xanthomas, reinforcing the diagnostic value of cutaneous signs as metabolic sentinels and highlighting that early dual-target treatment can prevent life-threatening complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.